GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » Capex-to-Operating-Cash-Flow

Forty Seven (Forty Seven) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Forty Seven Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Forty Seven's Capital Expenditure for the three months ended in Dec. 2019 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2019 was $-22.26 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Forty Seven Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Forty Seven's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forty Seven Capex-to-Operating-Cash-Flow Chart

Forty Seven Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Capex-to-Operating-Cash-Flow
- - - -

Forty Seven Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Forty Seven's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Forty Seven's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forty Seven's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forty Seven's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Forty Seven's Capex-to-Operating-Cash-Flow falls into.



Forty Seven Capex-to-Operating-Cash-Flow Calculation

Forty Seven's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2019 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.356) / -78.113
=N/A

Forty Seven's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2019 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -22.258
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forty Seven  (NAS:FTSV) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Forty Seven Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Forty Seven's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Forty Seven (Forty Seven) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1490 O’Brien Drive, Suite A, Menlo Park, CA, USA, 94025
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Executives
Dennis Henner director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball director C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads officer: Chief Financial Officer 4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c. 10 percent owner C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154